FIRST TRACKS BIOTHERAPEUTICS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
FIRST TRACKS BIOTHERAPEUTICS, INC. (TRAX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $102.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- FIRST TRACKS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $102.00K, a 77.78% decline year-over-year.
- FIRST TRACKS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- FIRST TRACKS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $459.00K.
- FIRST TRACKS BIOTHERAPEUTICS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $460.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month |
|---|---|---|
| 2026-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $102.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 | |
| 2025-06-30 | $459.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $919.00K 10-Q · filed 2026-08-12 |
| 2025-03-31 | $460.00K 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |